Abstract:Eradication of latent human immunodeficiency virus (HIV) infection is a global health challenge. Reactivation of HIV latency and killing of virus-infected cells, the so-called "kick and kill" or "shock and kill" approaches, are a popular strategy for HIV cure. While antiretroviral therapy (ART) halts HIV replication by targeting multiple steps in the HIV life cycle, including viral entry, integration, replication, and production, it cannot get rid of the occult provirus incorporated into the host-cell genome. These latent proviruses are replication-competent and can rebound in cases of ART interruption or cessation. In general, a very small population of cells harbor provirus, serve as reservoirs in ART-controlled HIV subjects, and are capable of expressing little to no HIV RNA or proteins. Beyond the canonical resting memory CD4(+) T cells, HIV reservoirs also exist within tissue macrophages, myeloid cells, brain microglial cells, gut epithelial cells, and hematopoietic stem cells (HSCs). Despite a lack of active viral production, latently HIV-infected subjects continue to exhibit aberrant cellular signaling and metabolic dysfunction, leading to minor to major cellular and systemic complications or comorbidities. These include genomic DNA damage; telomere attrition; mitochondrial dysfunction; premature aging; and lymphocytic, cardiac, renal, hepatic, or pulmonary dysfunctions. Therefore, the arcane machineries involved in HIV latency and its reversal warrant further studies to identify the cryptic mechanisms of HIV reservoir formation and clearance. In this review, we discuss several molecules and signaling pathways, some of which have dual roles in maintaining or reversing HIV latency and reservoirs, and describe some evolving strategies and possible approaches to eliminate viral reservoirs and, ultimately, cure/eradicate HIV infection.

The Rational Combination Strategy of Immunomodulatory Latency Reversing Agents and Novel Immunotherapy to Achieve HIV-1 Cure

Research progress on HIV latency-reversing agents and its mechanism

Recent progress on functional cure for acquired immunodeficiency syndrome

Moving Toward a Functional Cure for HIV-1

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Latency reversal and viral clearance to cure HIV-1

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Strategies for human immunodeficiency virus cure：current status and future prospects

HIV-1 functional cure: will the dream come true?

Functional cure for HIV:the approaches and challenges

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies

Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Targeting Viral Transcription for HIV Cure Strategies

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

The neglected brain reservoirs：a barrier to an HIV cure

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Interventions during Early Infection: Opening a Window for an HIV Cure?

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation